6月9日,默沙东宣布了三项3期临床试验中的前两项的阳性顶线结果,这些试验评估了enlicitide decanoate的安全性和有效性,enlicitide是一种研究性口服PCSK9抑制剂,正在评估其用于治疗成人高脂血症的降脂疗法,包括至少一种他汀类药物。与安慰剂(CORALreef HeFH)和其他口服非他汀类药物(CORALreef AddOn)相比,enlicitide的低密度脂蛋白胆固醇(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.